Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00381550

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:46.998466+00:00

Published At

2014-05-21T00:00:00+00:00

Record Updated At

2015-01-06

Results Posted At

2014-05-21

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Accelerated Phase Chronic Myelogenous Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Philadelphia Chromosome Negative Chronic Myelogenous Leukemia", "Polycythemia Vera", "Primary Myelofibrosis", "Relapsing Chronic Myelogenous Leukemia"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2015-01-06"

protocolSection.identificationModule.nctId

"NCT00381550"

protocolSection.identificationModule.officialTitle

"Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2014-05-21"

Study condition terms

• Accelerated Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (protocolSection.conditionsModule.conditions)
• Blastic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Chronic Eosinophilic Leukemia (protocolSection.conditionsModule.conditions)
• Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
• Essential Thrombocythemia (protocolSection.conditionsModule.conditions)
• Philadelphia Chromosome Negative Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Polycythemia Vera (protocolSection.conditionsModule.conditions)
• Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
• Relapsing Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.